177 Lu-RAD202

N/A

Report date: 2025/09/10 14:02:45

Base Information

Drug Name177 Lu-RAD202

Drug Alias Name177 Lu-RAD202

ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Radiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRadiopharm Theranostics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesRadiopharm Theranostics Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A